Skip To Main Content
Rashade Haynes II on Muck Rack

Rashade Haynes II

As seen in: Nature
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work. Claim your profile

Get in touch with Rashade

Contact Rashade, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Is this you?

As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile

Articles

SACF and GILA for in vitro transformation assessment of CRISPR/Cas9-edited cell therapy candidates: a multi-site study

|
By Lena Dorsheimer, Joana Ferreira, Bojing Wang, Rebecca Bohnert, Sabine Kaiser, Louise Delsing, Benoit Fischer, Andreas Schulz, Connie Chen, Lucilia Pereira Mouriès, Mick D Fellows, Silvana Libertini, Rashade Haynes II, Andreas Neerincx, Corinna Smolarek, Stefanie Könen, Kyle L. Kolaja, Ridhirama Bhuwania, Myriam Lemmens
| Nature Verified
Abstract Tumorigenicity is a key safety concern for CRISPR/Cas9-based gene therapies, yet its assessment remains challenging due to the lack of relevant and sensitive in vivo models. This HESI Global multi-site study evaluated the Soft Agar Colony Formation (SACF) assay and the Growth in Low Attachment (GILA) assay for in vitro transformation testing of CRISPR/Cas9-edited cells as part of tumorigenicity risk assessment.
Open in Who Shared Issue with article?
See all 1 articles